| General Information . | COMP . | SUP . |
|---|---|---|
| No. of samples (individuals) | 451 (215) | 66 (59) |
| Gender: female samples (individuals) | 256 (123) | 25 (23) |
| Gender: male samples (individuals) | 195 (92) | 41(36) |
| Age of individuals in years (mean) | 2–87 (42)a | 30–83 (59) |
| Vaccine type | … | … |
| AstraZeneca/ChAdOx1, no. of samples (%) | 124 (12) | 1 (0.5) |
| BioNTech/Comirnaty, no. of samples (%) | 599 (58) | 176 (87) |
| Janssen/Ad26.COV2.S9, no. of samples (%) | 92 (9) | - |
| Moderna/Spikevax, no. of samples (%) | 215 (21) | 26 (13) |
| Verified COVID | … | … |
| COVID, no. of individuals (%) | 104 (48) | 27 (46) |
| Hospitalization, no. of individuals (%) | 3 (1.4) | 6 (10) |
| COVID in individuals with 3–4 vaccinations (%) | 59 (27) | 17 (29) |
| COVID in individuals with 3–4 vaccinations within 3 mo after last vaccination (%) | 45 (21) | 5 (8) |
| Sampling timepoint after immunization | … | … |
| Sampling after last immunization in months (mean) | 0.1–17 (3.3)b | 0.4–13.4 (3.8)c |
| Sampling after last vaccination in months (mean) | 0.1–13.6 (3.2) | 0.4–11.3 (3.7) |
| Sampling after last infection in months (mean) | 0.3–17 (2.9) | 0.9–13.4 (4.0) |
| No. of samples tested against virus strain | … | … |
| A, no. of samples (mean/median titer) | 414 (1457/640) | 66 (710/120) |
| D, no. of samples (mean/median titer) | 434 (1429/640) | 66 (1025/80) |
| BA.1, no of samples (mean/median titer) | 391 (615/160) | 66 (202/80) |
| XBB.1.5, no of samples (mean/median titer) | 123 (47/40) | 10 (124/80) |
| General Information . | COMP . | SUP . |
|---|---|---|
| No. of samples (individuals) | 451 (215) | 66 (59) |
| Gender: female samples (individuals) | 256 (123) | 25 (23) |
| Gender: male samples (individuals) | 195 (92) | 41(36) |
| Age of individuals in years (mean) | 2–87 (42)a | 30–83 (59) |
| Vaccine type | … | … |
| AstraZeneca/ChAdOx1, no. of samples (%) | 124 (12) | 1 (0.5) |
| BioNTech/Comirnaty, no. of samples (%) | 599 (58) | 176 (87) |
| Janssen/Ad26.COV2.S9, no. of samples (%) | 92 (9) | - |
| Moderna/Spikevax, no. of samples (%) | 215 (21) | 26 (13) |
| Verified COVID | … | … |
| COVID, no. of individuals (%) | 104 (48) | 27 (46) |
| Hospitalization, no. of individuals (%) | 3 (1.4) | 6 (10) |
| COVID in individuals with 3–4 vaccinations (%) | 59 (27) | 17 (29) |
| COVID in individuals with 3–4 vaccinations within 3 mo after last vaccination (%) | 45 (21) | 5 (8) |
| Sampling timepoint after immunization | … | … |
| Sampling after last immunization in months (mean) | 0.1–17 (3.3)b | 0.4–13.4 (3.8)c |
| Sampling after last vaccination in months (mean) | 0.1–13.6 (3.2) | 0.4–11.3 (3.7) |
| Sampling after last infection in months (mean) | 0.3–17 (2.9) | 0.9–13.4 (4.0) |
| No. of samples tested against virus strain | … | … |
| A, no. of samples (mean/median titer) | 414 (1457/640) | 66 (710/120) |
| D, no. of samples (mean/median titer) | 434 (1429/640) | 66 (1025/80) |
| BA.1, no of samples (mean/median titer) | 391 (615/160) | 66 (202/80) |
| XBB.1.5, no of samples (mean/median titer) | 123 (47/40) | 10 (124/80) |
Abbreviations: COMP, immunocompetent individual; SUP, immunocompromised individual.
aTwo samples were excluded from this category because of missing data.
bThree samples were excluded from this category because of missing data.
cOne sample was excluded from this category because of missing data.
| General Information . | COMP . | SUP . |
|---|---|---|
| No. of samples (individuals) | 451 (215) | 66 (59) |
| Gender: female samples (individuals) | 256 (123) | 25 (23) |
| Gender: male samples (individuals) | 195 (92) | 41(36) |
| Age of individuals in years (mean) | 2–87 (42)a | 30–83 (59) |
| Vaccine type | … | … |
| AstraZeneca/ChAdOx1, no. of samples (%) | 124 (12) | 1 (0.5) |
| BioNTech/Comirnaty, no. of samples (%) | 599 (58) | 176 (87) |
| Janssen/Ad26.COV2.S9, no. of samples (%) | 92 (9) | - |
| Moderna/Spikevax, no. of samples (%) | 215 (21) | 26 (13) |
| Verified COVID | … | … |
| COVID, no. of individuals (%) | 104 (48) | 27 (46) |
| Hospitalization, no. of individuals (%) | 3 (1.4) | 6 (10) |
| COVID in individuals with 3–4 vaccinations (%) | 59 (27) | 17 (29) |
| COVID in individuals with 3–4 vaccinations within 3 mo after last vaccination (%) | 45 (21) | 5 (8) |
| Sampling timepoint after immunization | … | … |
| Sampling after last immunization in months (mean) | 0.1–17 (3.3)b | 0.4–13.4 (3.8)c |
| Sampling after last vaccination in months (mean) | 0.1–13.6 (3.2) | 0.4–11.3 (3.7) |
| Sampling after last infection in months (mean) | 0.3–17 (2.9) | 0.9–13.4 (4.0) |
| No. of samples tested against virus strain | … | … |
| A, no. of samples (mean/median titer) | 414 (1457/640) | 66 (710/120) |
| D, no. of samples (mean/median titer) | 434 (1429/640) | 66 (1025/80) |
| BA.1, no of samples (mean/median titer) | 391 (615/160) | 66 (202/80) |
| XBB.1.5, no of samples (mean/median titer) | 123 (47/40) | 10 (124/80) |
| General Information . | COMP . | SUP . |
|---|---|---|
| No. of samples (individuals) | 451 (215) | 66 (59) |
| Gender: female samples (individuals) | 256 (123) | 25 (23) |
| Gender: male samples (individuals) | 195 (92) | 41(36) |
| Age of individuals in years (mean) | 2–87 (42)a | 30–83 (59) |
| Vaccine type | … | … |
| AstraZeneca/ChAdOx1, no. of samples (%) | 124 (12) | 1 (0.5) |
| BioNTech/Comirnaty, no. of samples (%) | 599 (58) | 176 (87) |
| Janssen/Ad26.COV2.S9, no. of samples (%) | 92 (9) | - |
| Moderna/Spikevax, no. of samples (%) | 215 (21) | 26 (13) |
| Verified COVID | … | … |
| COVID, no. of individuals (%) | 104 (48) | 27 (46) |
| Hospitalization, no. of individuals (%) | 3 (1.4) | 6 (10) |
| COVID in individuals with 3–4 vaccinations (%) | 59 (27) | 17 (29) |
| COVID in individuals with 3–4 vaccinations within 3 mo after last vaccination (%) | 45 (21) | 5 (8) |
| Sampling timepoint after immunization | … | … |
| Sampling after last immunization in months (mean) | 0.1–17 (3.3)b | 0.4–13.4 (3.8)c |
| Sampling after last vaccination in months (mean) | 0.1–13.6 (3.2) | 0.4–11.3 (3.7) |
| Sampling after last infection in months (mean) | 0.3–17 (2.9) | 0.9–13.4 (4.0) |
| No. of samples tested against virus strain | … | … |
| A, no. of samples (mean/median titer) | 414 (1457/640) | 66 (710/120) |
| D, no. of samples (mean/median titer) | 434 (1429/640) | 66 (1025/80) |
| BA.1, no of samples (mean/median titer) | 391 (615/160) | 66 (202/80) |
| XBB.1.5, no of samples (mean/median titer) | 123 (47/40) | 10 (124/80) |
Abbreviations: COMP, immunocompetent individual; SUP, immunocompromised individual.
aTwo samples were excluded from this category because of missing data.
bThree samples were excluded from this category because of missing data.
cOne sample was excluded from this category because of missing data.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
